Skip to content

Whole- Body Vibration Among Egyptian Elderly With Sarcopenia

Comparative Effectiveness of Whole- Body Vibration and Aerobic Training Among Egyptian Elderly With Sarcopenia

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06293573
Acronym
WBV
Enrollment
84
Registered
2024-03-05
Start date
2024-01-01
Completion date
2025-12-01
Last updated
2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Keywords

Sarcopenia, Elderly, Performance, Whole body vibration, Aerobic exercises

Brief summary

To investigate and compare between the effectiveness of whole body vibration and aerobic training exercises in management of sarcopenia, muscle mass, physical performance and muscle strength in elderly.

Detailed description

Participants will be assigned randomly into two groups of equal number (study group A and study group B ) the randomization will be performed by computerized randomization. Assessors will be blinded to the groups of the subjects. c- Subject selection 84 patients with sarcopenia will participate in this study and will be divided randomly into three equal groups with 28 participants in each group. d- Groups: Group A (Study group): Will receive whole body vibration exercises with conventional progressive resistance exercises and diet modification life style Group B (Study group): Will receive aerobic exercises training with conventional progressive resistance exercises and diet modification life style. Group C (Control Group): will receive conventional progressive resistance exercises and diet modification life style. During the study, the participants will receive study information form, instructions and signed the consent form.

Interventions

GROUP A : will receive whole body vibration exercises combined with resistance exercises

OTHERaerobic exercises

Group B will receive aerobic exercises training combined with progressive resistance exercises with diet modification life style.

Group c: will receive progressive resistance exercises with diet modification life style.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants will be assigned randomly into three groups of equal number (study group A, study group B, and group C) the randomization will be performed by computerized randomization. Assessors will be blinded to the groups of the subjects.

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. patients age older than 60 years 2. patients with Skeletal muscle index (SMI) below 8.87 kg/m2 and 6.42 kg/m2 in males and females, respectively. 3. patients with hand grip strength below \< 27 kg in men and \< 16 kg in women. 4. patients with no regular exercise habit for more than 3 months . 5. patients with gait speed \> 0.8 m/s. 6. patients with proper conscious and cognition that will be detected by using Mini Mental State Examination(scores \> 21). \-

Exclusion criteria

acute injury. 2- severe heart diseases. 3- pacemaker. 4-history of orthopedic surgery of the lower limbs and/or fracture less than 1 year earlier. .5 - inability to walk without assistance. 6-neurological diseases or acute conditions that would interfere with testing and training. 7-patients with improper conscious and cognition that will be detected by using Mini Mental State Examination(scores \< 21). 8- patients who cannot exercise at all due to conditions like deep vein thrombosis or blood clotting issues. 9- patients with severe illnesses that influence assessments and interventions, such as those with disabilities or musculoskeletal conditions (such as fracture, dislocation, osteoporosis, and rheumatoid arthritis). 10- People with major spinal conditions or surgical histories, such as cauda equina syndrome, tumor, vertebral fracture, inflammatory joint disease, spondylolisthesis, and ankylosing spondylitis. Every participant will get a primary checkup to get a full picture of their health, find out if there are any restrictions, and decide whether they can take part in the study. \-

Design outcomes

Primary

MeasureTime frameDescription
Muscle MassMuscle mass will be investigated at baseline and after the treatment period of 12 weeks.Outcome measures included: • Skeletal muscle mass (SMM): will be measured by Bioimpedance analysis using body composition analyzer (InBody Dial H 20b).
muscle strengthMuscle strength will be investigated at baseline and after the treatment period of 12 weeks.will be measured by using calibrated handheld dynamometer (CAMRY EH101).
timed Up and Go Test (TUG)Timed Up and Go Test will be investigated at baseline and after the treatment period of 12 weeks.The TUG test evaluates physical function, individuals will be asked to rise from a standard chair, walk to a marker 3 m away from the chair, turn around, walk back, and sit down again.
Gait Speed testGait speed test will be investigated at baseline and after the treatment period of 12 weeks.The 4-m usual walking speed test, which measures speed either manually ,with a stopwatch or instrumentally, with an electronic device, to measure gait timing.
400 m Walking Test400 m Walking Test will be investigated at baseline and after the treatment period of 12 weeks.The 400-meters walk test evaluates a person's stamina and ability to walk. Participants in this test are required to run 20 laps of 20 meters, each lap as quickly as they can, and are permitted up to two rest breaks throughout the test.
Six minute walk test (6MWT)Six Minutes Walk Test will be investigated at baseline and after the treatment period of 12 weeks.6MWT is used to measure a patient's exercise tolerance. Also it is used to assess aerobic capacity and endurance. Patient is asked to walk at his normal pace for six minutes.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026